Profile: Amgen Inc (AMGN.O)
27 Sep 2016
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company's business segment is human therapeutics. The Company's marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Company focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
The Company's product candidates in Phase III programs include AMG 334 for Episodic migraine; Aranesp for Myelodysplastic syndromes; BLINCYTO for acute lymphoblastic leukemia (ALL); ENBREL for Psoriatic arthritis and Rheumatoid arthritis remission; IMLYGIC for Metastatic melanoma; Kyprolis for Multiple myeloma; Parsabiv for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) receiving dialysis; Prolia for Glucocorticoid-induced osteoporosis; Repatha for Hyperlipidemia, and Romosozumab for Postmenopausal osteoporosis and Male osteoporosis. The Company's product candidates in Phase II programs include AMG 157 for Asthma and Atopic dermatitis; AMG 181 for inflammatory bowel diseases; AMG 334 for chronic migraine; AMG 520 for Alzheimer's disease; AMG 899 for Dyslipidemia, and Omecamtiv mecarbil for heart failure. Its product candidates in Phase I programs include AMG 211 for various cancer types; AMG 224 for Multiple myeloma; AMG 228 for solid tumors; AMG 301 for migraine; AMG 319 for Hematologic malignancies; AMG 330 for Acute myeloid leukemia; AMG 357 for autoimmune diseases; AMG 557 for Systemic lupus erythematosus; AMG 581 for Schizophrenia, and AMG 592 for inflammatory diseases.
The Company markets ENBREL primarily in the United States. ENBREL is used primarily in the indications for the treatment of adult patients with various conditions, such as moderately to severely active rheumatoid arthritis, chronic moderate-to-severe plaque psoriasis patients, and active psoriatic arthritis. The Company markets Neulasta, a pegylated protein based on the filgrastim molecule, primarily in the United States and Europe. Neulasta is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count. It markets Aranesp primarily in Europe and in the United States. Aranesp is indicated for the treatment of anemia caused by CKD (in both patients on dialysis and patients not on dialysis). Aranesp is also indicated for the treatment of anemia due to concomitant myelosuppressive chemotherapy in patients with non-myeloid malignancies. The Company markets EPOGEN in the United States for dialysis patients. It markets EPOGEN for the indication to treat a lower-than-normal number of red blood cells (anemia) caused by CKD in patients on dialysis to lessen the need for red blood cell transfusions.
The Company markets cinacalcet as Sensipar primarily in the United States and as Mimpara primarily in Europe. Cinacalcet is used primarily in the indication for the treatment of SHPT in adult patients with CKD on dialysis. The Company markets XGEVA primarily in the United States and Europe. XGEVA is used primarily in the indication for the prevention of skeletal-related events (SREs), such as pathological fracture, radiation to bone, spinal cord compression or surgery to bone, in patients with bone metastases from solid tumors. It markets Prolia primarily in the United States and Europe. In the United States, Prolia is used primarily in the indication for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture, or patients having failed or are intolerant to other available osteoporosis therapy. In Europe, Prolia is used primarily for the treatment of osteoporosis in postmenopausal women at increased risk of fractures. It markets NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), primarily in the United States, Canada and Europe. NEUPOGEN is used primarily in the indication to help reduce the chance of infection due to a low white blood cell count, in people with certain types of cancer (non-myeloid) receiving anti-cancer medicines (chemotherapy) that can cause fever and a low blood cell count.
The Company competes with Johnson & Johnson, Merck & Company, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Galenica Group, F. Hoffmann-La Roche Ltd., Novartis, Eli Lilly, Bristol-Myers Squibb Company, Merck KGaA, Takeda Pharmaceutical Company Limited, Celgene Corporation and Regeneron Pharmaceuticals, Inc.
1 Amgen Center Dr
THOUSAND OAKS CA 91320-1730
Company Web Links
- UPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study
- FDA approves Amgen's copy of AbbVie arthritis drug Humira
- U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira
- Amgen cholesterol drug reduces arterial plaque buildup: study
- BRIEF-Amgen announces positive top line results from Phase 3 GLAGOV imaging study of Repatha(evolocumab)